Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: A retrospective analysis

Journal of Thoracic Disease

Volumn 2, Issue 1, 2010, Pages 16-20

  Pusceddu, S ^a   Catena, L ^a   Valente, M ^a   Buzzoni, R ^a   Formisano, B ^a   Del Vecchio, M ^a   Ducceschi, M ^a   Tavecchio, L ^a   Fabbri, A ^a   Bajetta, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Carcinoid; Lung cancer; Neuroendocrine; Pulmonary

Indexed keywords

EID: 84861964989     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pearse A. The cytochemistry and ultrastructure of polypeptide hormone producing cells of APUD series and the embryologic, physiologic and pathologic implications of the concept. J histochem Cytochem 1969;17:303-13.
2. Travis WD, Corrin B, Shimosato Y, Brambilla E. The histological typing of lung and pleural tumors. In: WHO/IASLC Classification of Lung and Pleural Tumors. 3rd ed. Berlin: Springer; 1999.
3. Chugta T, Morin J, Sheiner N, Wilson J, Mulder D. Bronchial carcinoid: twenty years experience defines selective surgical approach. Surgery 1997;122:801-8.
4. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman MP, et al. Survival from rare cancer in adults: a population-based study. Lancet Oncol. 2006; 7:132-40.
5. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001;119:1647-51.
6. Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005;29:179-87.
7. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5-21.
8. Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA, Miller JI. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 2001;119:14-8.
9. Hage R, de la Rivière AB, Seldenrijk CA, van den Bosch JM. Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol 2003;10:697-704.
10. Kosmidis PA. Treatment of carcinoid of the lung. Curr Opin Oncol 2004;16: 146-9.
11. Katai M, Sakurai A, Inaba H, Ikeo Y, Yamauchi K, Hashizume K. Octreotide as a rapid and effective painkiller for metastatic carcinoid tumor. Endocr J 2005;52: 277-80.
12. Garcia-Yuste M, Molins L, Matilla JM, Gonzalez-Aragoneses F, Lopez-Pujol J, Ramos G, et al. Trends in prognostic factors for neuroendocrine lung tumors: analys of the experience of the Spanish multicentre study of neurendocrine tumours of the lung. Arch Bronconeumol 2007;43:549-56.
13. Filosso PL, Rena O, Donati G. Bronchial carcinoid tumors: surgical management and long-term out come. J Thorac Cardiovasc Surg 2002;123:303-9.
14. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-44.
15. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000;31:1255-65.
16. Zuetenhorst JM, Korse CM, Bonfrer JM, Peter E, Lamers CB, Taal BG. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors. Clin Chem 2004;50:1634-9.
17. Granberg D, Eriksson B, Wilander E, Grimfjard P, Fjallskog ML, Oberg K, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001;12:1383-91.
18. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59:637-42.
19. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998;83:372-8.
20. Ferrari L, Della Torre S, Collini P, Martinetti A, Procopio G, De Dosso S, et al. Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. Tumori 2006;92:531-5.
21. De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, et al. Pulmonary carcinoid tumours: indolent but not benign. Oncology 2007;73:162-8.
22. Bajetta E, Procopio G, Pusceddu S, Pietrantonio F, Milione M, Maccauro M, et al. From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncol Rev 2009;3:79-87.
23. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002;13:614-21.